BEZ:LSEBeazley Plc Analysis
Data as of 2026-03-14 - not real-time
£1,288.00
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Beazley plc is trading at £12.88 (1288 GBp), comfortably above its 20‑day, 50‑day and 200‑day moving averages, indicating a short‑term bullish bias, but the RSI of 77.8 points to an overbought condition and the MACD histogram is negative, signaling bearish momentum. The stock’s PE ratio of 11.9 sits well below the industry average of 16.35, while the dividend yield of 1.94% is supported by a robust cash position of £11.98 bn against modest debt of £0.64 bn, suggesting sustainable payouts. Analyst consensus remains a hold with median price targets around £13.22, yet recent coverage notes a trimmed fair‑value estimate to £12.20 and a split view between earnings strength and underwriting execution risks, adding to near‑term uncertainty.
Over the longer horizon, Beazley’s solid ROE of 19.3%, low beta of 0.23, and stable volume profile underpin a resilient risk profile, while the specialty insurance segments (cyber, MAP, property) offer modest growth opportunities. The combination of strong balance‑sheet metrics, attractive valuation relative to peers, and a sustainable dividend makes the stock a compelling buy for patient investors, despite short‑term technical softness and mixed analyst sentiment.
Over the longer horizon, Beazley’s solid ROE of 19.3%, low beta of 0.23, and stable volume profile underpin a resilient risk profile, while the specialty insurance segments (cyber, MAP, property) offer modest growth opportunities. The combination of strong balance‑sheet metrics, attractive valuation relative to peers, and a sustainable dividend makes the stock a compelling buy for patient investors, despite short‑term technical softness and mixed analyst sentiment.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- RSI overbought at 77.8
- Bearish MACD histogram
- Mixed analyst targets and recent fair‑value trim
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- PE well below industry average
- Strong cash generation and low leverage
- Sustainable dividend yield of 1.94%
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Robust ROE of 19.3% and solid free cash flow
- Low beta indicating defensive characteristics
- Growth potential in specialty lines such as cyber and MAP risks
Key Metrics & Analysis
Financial Health
Revenue Growth1.10%
Profit Margin15.37%
P/E Ratio11.9
ROE19.27%
ROA6.04%
Debt/Equity13.08
P/B Ratio207.9
Op. Cash Flow£1.3B
Free Cash Flow£1.0B
Industry P/E16.4
Technical Analysis
TrendBullish
RSI77.8
Support£1,209.00
Resistance£1,295.00
MA 20£1,258.60
MA 50£1,138.01
MA 200£937.41
MACDBearish
VolumeStable
Fear & Greed Index72.88
Valuation
Fair Value£4,459.15
Target Price£1,318.66
Upside/Downside2.38%
GradeFair
TypeBlend
Dividend Yield1.94%
Risk Assessment
Beta0.23
Volatility23.32%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.